CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F22%3A10443920" target="_blank" >RIV/00216208:11130/22:10443920 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/22:10443920
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=z8Xo_oc801" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=z8Xo_oc801</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/pbc.29779" target="_blank" >10.1002/pbc.29779</a>
Alternative languages
Result language
angličtina
Original language name
CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics
Original language description
Daratumumab, an anti-CD38 antibody, is used experimentally in the treatment of relapsed acute lymphoblastic leukemia (ALL). We treated five patients suffering from relapsed ALL with daratumumab. Four patients had T ALL, three of whom achieved complete remission (CR) after treatment and underwent stem cell transplant (SCT). Two of them had a second relapse and died 6 and 8 months after SCT, respectively. One transplanted T ALL patient remained in CR2 15 months after relapse. In the remaining T-ALL patient, the disease progressed under daratumumab treatment, and the patient died early after the first relapse. The B-cell precursor ALL patient with a second CD19-negative relapse, whose disease turned out to be resistant to the combination of daratumumab with chemotherapy, later achieved CR3 with inotuzumab ozogamicin, underwent SCT and remained in CR3. Leukemia burden should be monitored after daratumumab, and care should be taken not to misclassify leukemic cells with false negativity of surface CD38; using an antibody reacting with nondaratumumab epitopes is advantageous.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NU20-03-00284" target="_blank" >NU20-03-00284: Antigen receptor rearrangement profiling in immune monitoring and treatment response prediction of malignant diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pediatric Blood and Cancer
ISSN
1545-5009
e-ISSN
1545-5017
Volume of the periodical
69
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
e29779
UT code for WoS article
000797773300001
EID of the result in the Scopus database
2-s2.0-85130352541